Berinert denied for missing prior authorization by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for berinert are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BlueCross BlueShield Requires Prior Authorization for Berinert

Berinert is a high-cost specialty biologic used to treat acute hereditary angioedema (HAE) attacks, and BCBS routinely requires prior authorization (PA) before covering it. A "prior-auth-required" denial means either that a PA was not obtained before the drug was dispensed or administered, that the PA request was submitted but denied for unmet criteria, or that a previous authorization lapsed and was not renewed. Because HAE attacks are acute and unpredictable, patients and providers sometimes must use Berinert before authorization can be obtained — creating retroactive denial situations. Both prospective and retroactive PA denials are appealable, and HAE's acute, potentially life-threatening nature supports urgent and expedited review pathways.

## Your Appeal Rights

Under ACA Section 2719 and ERISA Section 503, you have the right to a full-and-fair internal appeal and, if upheld, independent external review through an accredited IRO. File the external-review request within four months of the final adverse determination. Expedited review (72-hour decision) is available when a standard timeline could jeopardize your health — this standard is readily met for a patient with active HAE who needs ongoing access to acute treatment. For retroactive denials following an emergency use, frame the appeal as a medical-emergency retrospective review.

## The Appeal Process

1. Request the denial letter and the BCBS prior-authorization criteria document for Berinert. 2. Determine whether the denial is prospective (PA not yet obtained) or retroactive (used during an acute attack before PA was in place). 3. For prospective denials: work with the treating specialist to submit a complete PA with all required documentation. 4. For retroactive/emergency denials: file an appeal citing the acute, emergent nature of the HAE attack and the inability to delay treatment. 5. File Level 1 internal appeal, then Level 2, then external IRO review if needed.

## Documentation to Gather

• HAE diagnosis confirmation: Genetic or laboratory confirmation of the specific HAE type, matching the criteria in BCBS's PA policy.
• Attack history and severity: Physician documentation of attack frequency, severity, affected body regions (particularly laryngeal or abdominal attacks), and any related emergency visits or hospitalizations.
• Prescriber specialty and clinical rationale: A letter from the treating allergist, immunologist, or HAE specialist addressing each PA criterion, confirming the diagnosis, attack burden, and the clinical appropriateness of Berinert.
• Emergency-use records (if retroactive): Emergency department records, infusion facility notes, or home-administration records documenting the acute attack that required immediate treatment, establishing that delay would have been medically dangerous.
• Prior treatment history: Records of any previously tried HAE acute treatments with outcomes, if the BCBS policy requires a trial of an alternative agent.
• Prior authorization history: Any previous BCBS PA approvals for Berinert for this patient, to support continuity-of-care and demonstrate established medical necessity.

## Criteria-Mapping Structure

Obtain the BCBS PA criteria document for Berinert and map each requirement:

| BCBS PA Criterion | Satisfying Documentation | |---|---| | Confirmed HAE diagnosis with type specified | Lab/genetic results + specialist confirmation | | Attack frequency / severity (per policy) | Attack log + specialist summary | | Prescriber specialty requirement (if any) | Treating specialist credentials and specialty | | Prior HAE treatment requirement (if any) | Treatment history with dates and outcomes | | Emergency/acute-use exception (if retroactive) | ER or infusion records documenting acute attack |

For retroactive denials, the appeal letter should lead with the emergent clinical circumstances — BCBS cannot hold a patient to a prospective PA standard when the nature of an acute HAE attack made prior authorization practically impossible.